← Back to Home

Formosa Pharmaceuticals Files European Trial Application for TSY-110, Advancing HER2 Breast Cancer ADC Biosimilar

TSY-110, jointly developed with EirGenix, is planned for comparison with the originator product Kadcyla in safety, pharmacokinetics, and immunogenicity. The application brings development another step closer to testing in humans, but clinical and regulatory hurdles remain before it can potentially offer a more affordable treatment option.

By SURL BioNews

Antibody-drug conjugates (ADCs) use antibodies to carry cytotoxic drugs and are among the treatment tools for HER2-positive breast cancer. The challenge for biosimilar developers is to demonstrate that this complex combination is sufficiently similar to the originator product. On August 28, 2026, Formosa Pharmaceuticals announced that it had submitted a clinical trial application for TSY-110 to European regulatory authorities, preparing for a pivotal trial using Roche’s Kadcyla as the comparator.

TSY-110, also known as EG12043, is jointly developed by Formosa Pharmaceuticals and EirGenix. Its reference product, Kadcyla, contains ado-trastuzumab emtansine and is used in specific settings of HER2-positive early and metastatic breast cancer. This announcement concerns the submission of a trial application; it does not mean the trial has been authorized to begin or that the product has received marketing authorization.

According to the company’s announcement, the planned trial will compare the two products’ safety, tolerability, pharmacokinetics, and immunogenicity. These assessments are intended to address questions including whether drug concentrations change similarly after administration in humans and whether the immune system mounts a response against the drug. For a biosimilar, the focus is on establishing evidence of similarity to the reference product, rather than claiming superior efficacy over the originator.

Such comparisons also extend to manufacturing. TSY-110 links the HER2-recognizing antibody trastuzumab to a cytotoxic drug, and the amount of drug carried by each antibody is one of the product’s characteristics. Formosa Pharmaceuticals stated that preclinical evaluations had shown high biosimilarity, a stable drug-to-antibody ratio, and plasma pharmacokinetics similar to those of the reference product. However, the announcement did not include complete data, and these claims still need to be assessed through subsequent publicly available information and regulatory review.

In its August 31 report on the same event, BioSpectrum Asia added that the development team had completed a biosimilar development Type II meeting with the US Food and Drug Administration in 2026, reaching broad agreement on the direction of the clinical trial design and the chemistry, manufacturing, and controls strategy. The report also noted that the program combines EirGenix’s antibody technology with Formosa Laboratories’ ADC bioconjugation platform. These preparations help align clinical and manufacturing requirements, but regulatory consultation itself does not constitute approval.

Currently available public information does not specify the trial’s enrollment size, detailed eligibility criteria, comparison criteria, or completion timeline, and no human results from this trial are available. What can be confirmed at this stage is therefore that the development process has moved forward; this does not yet establish that TSY-110 has demonstrated comparable performance to Kadcyla in patients.

Formosa Pharmaceuticals and EirGenix have identified improving treatment access as a development goal, but the announcement provided no pricing or quantifiable cost differences. For patients and healthcare systems, the significance of this program will ultimately depend on whether it can establish sufficient evidence of similarity, obtain approval, and translate manufacturing and supply capabilities into a treatment option that is available in practice.

References

  1. The Malaysian Reserve
  2. Formosa Pharmaceuticals, Inc.
  3. BioSpectrum Asia